Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

G Metro, A Passaro, G Lo Russo, L Bonanno, R Giusti, V Gregorc, E Capelletto, O Martelli, FL Cecere, D Giannarelli, A Luciani, A Bearz, Alessandro Tuzi, Vieri Scotti, G Tonini, D Galetta, Annamaria Carta, H Soto Parra, A Rebonato, A MorabitoR Chiari

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome. © 2018 2018 Future Medicine Ltd.
Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalFuture Oncology
Volume14
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this